Genmab A/S Stock Forecast, Price & News

-0.58 (-1.35 %)
(As of 09/16/2021 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
Volume461,996 shs
Average Volume521,634 shs
Market Capitalization$27.77 billion
P/E Ratio68.19
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive GMAB News and Ratings via Email

Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter.

Genmab A/S logo

About Genmab A/S

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value





Social Links


Overall MarketRank

1.76 out of 5 stars

Medical Sector

825th out of 1,352 stocks

Pharmaceutical Preparations Industry

405th out of 665 stocks

Analyst Opinion: 2.1Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Genmab A/S (NASDAQ:GMAB) Frequently Asked Questions

Is Genmab A/S a buy right now?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Genmab A/S in the last twelve months. There are currently 3 sell ratings, 5 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Genmab A/S stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GMAB, but not buy additional shares or sell existing shares.
View analyst ratings for Genmab A/S
or view top-rated stocks.

What stocks does MarketBeat like better than Genmab A/S?

Wall Street analysts have given Genmab A/S a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Genmab A/S wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Genmab A/S?

Genmab A/S saw a drop in short interest in the month of August. As of August 31st, there was short interest totaling 1,190,000 shares, a drop of 26.1% from the August 15th total of 1,610,000 shares. Based on an average trading volume of 481,200 shares, the days-to-cover ratio is currently 2.5 days.
View Genmab A/S's Short Interest

When is Genmab A/S's next earnings date?

Genmab A/S is scheduled to release its next quarterly earnings announcement on Wednesday, November 3rd 2021.
View our earnings forecast for Genmab A/S

How were Genmab A/S's earnings last quarter?

Genmab A/S (NASDAQ:GMAB) posted its earnings results on Wednesday, May, 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.05 by $0.22. The firm earned $256.24 million during the quarter, compared to analysts' expectations of $214.90 million. Genmab A/S had a trailing twelve-month return on equity of 13.07% and a net margin of 34.37%.
View Genmab A/S's earnings history

How has Genmab A/S's stock been impacted by COVID-19 (Coronavirus)?

Genmab A/S's stock was trading at $20.60 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, GMAB stock has increased by 105.2% and is now trading at $42.28.
View which stocks have been most impacted by COVID-19

What guidance has Genmab A/S issued on next quarter's earnings?

Genmab A/S issued an update on its FY 2021 earnings guidance on Wednesday, September, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.18 billion-$1.28 billion, compared to the consensus revenue estimate of $1.27 billion.

What price target have analysts set for GMAB?

14 brokers have issued 12 month price objectives for Genmab A/S's stock. Their forecasts range from $37.00 to $55.00. On average, they anticipate Genmab A/S's stock price to reach $44.71 in the next year. This suggests a possible upside of 5.8% from the stock's current price.
View analysts' price targets for Genmab A/S
or view top-rated stocks among Wall Street analysts.

Who are Genmab A/S's key executives?

Genmab A/S's management team includes the following people:
  • Jan G. J. van de Winkel, President & Chief Executive Officer
  • Anthony Mancini, Chief Operating Officer & Executive Vice President
  • Anthony Pagano, Chief Financial Officer & Executive Vice President
  • Tahamtan Ahmadi, Chief Medical Officer & Executive Vice President
  • Judith Klimovsky, Chief Development Officer & Executive VP

Who are some of Genmab A/S's key competitors?

What other stocks do shareholders of Genmab A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genmab A/S investors own include NVIDIA (NVDA), Alibaba Group (BABA), Johnson & Johnson (JNJ), CVS Health (CVS), The Home Depot (HD), Intel (INTC), Pfizer (PFE), PayPal (PYPL), Verizon Communications (VZ) and Cisco Systems (CSCO).

When did Genmab A/S IPO?

(GMAB) raised $503 million in an IPO on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers.

What is Genmab A/S's stock symbol?

Genmab A/S trades on the NASDAQ under the ticker symbol "GMAB."

Who are Genmab A/S's major shareholders?

Genmab A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.17%), Macquarie Group Ltd. (0.63%), Capital International Investors (0.54%), Artisan Partners Limited Partnership (0.50%), Price T Rowe Associates Inc. MD (0.30%) and Goldman Sachs Group Inc. (0.27%).

Which major investors are selling Genmab A/S stock?

GMAB stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Northern Trust Corp, Credit Suisse AG, Wells Fargo & Company MN, First Light Asset Management LLC, Morgan Stanley, Morgan Stanley, and Renaissance Technologies LLC.

Which major investors are buying Genmab A/S stock?

GMAB stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., BlackRock Inc., First Trust Advisors LP, Hardman Johnston Global Advisors LLC, Capital International Investors, Bank of America Corp DE, Bank of America Corp DE, and Point72 Asset Management L.P..

How do I buy shares of Genmab A/S?

Shares of GMAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Genmab A/S's stock price today?

One share of GMAB stock can currently be purchased for approximately $42.28.

How much money does Genmab A/S make?

Genmab A/S has a market capitalization of $27.77 billion and generates $1.55 billion in revenue each year. The company earns $728.93 million in net income (profit) each year or $1.12 on an earnings per share basis.

How many employees does Genmab A/S have?

Genmab A/S employs 781 workers across the globe.

When was Genmab A/S founded?

Genmab A/S was founded in 1999.

What is Genmab A/S's official website?

The official website for Genmab A/S is

Where are Genmab A/S's headquarters?

Genmab A/S is headquartered at Kalvebod Brygge 43, Copenhagen G7, 1560.

How can I contact Genmab A/S?

Genmab A/S's mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company can be reached via phone at (457) 020-2728 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.